OTCMKTS:GNFTF Genfit (GNFTF) Stock Price, News & Analysis → [BUY ALERT] Our #1 A.I. Stock for March (From Behind the Markets) (Ad) Free GNFTF Stock Alerts $2.98 0.00 (0.00%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$2.98▼$2.9850-Day Range$2.98▼$3.4552-Week Range$2.98▼$3.45VolumeN/AAverage Volume1,225 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest Get Genfit alerts: Email Address Ad Paradigm PressForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.Click here to find out that this 8,788% cryptocurrency is. About Genfit Stock (OTCMKTS:GNFTF)Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.Read More GNFTF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GNFTF Stock News HeadlinesMarch 8, 2024 | msn.comInventiva resumes Phase 3 study for NASH drug, stock up 6%December 11, 2023 | markets.businessinsider.comOptimistic Outlook for Genfit: Justine Telliez Raises Target Price Amid Positive Drug DevelopmentsMarch 29, 2024 | Prosper Trading Academy (Ad)Did you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:December 9, 2023 | markets.businessinsider.comBuy Rating Affirmed for Genfit SA on Strong Elafibranor Efficacy and Favorable Regulatory ProspectsDecember 8, 2023 | markets.businessinsider.comGENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC)November 15, 2023 | lse.co.ukGenfit Share Price (GNFT.PA)November 14, 2023 | marketwatch.comIpsen, Genfit Drug Fights Liver Disease Progression, Phase-Three Trial FindsNovember 12, 2023 | seekingalpha.comGenfit reports 9M resultsMarch 29, 2024 | Prosper Trading Academy (Ad)Did you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:September 23, 2023 | markets.businessinsider.comKepler Capital Sticks to Their Buy Rating for Genfit (GNFTF)July 4, 2023 | markets.businessinsider.comSVB Securities Remains a Buy on Genfit SA (GNFT)June 30, 2023 | marketwatch.comGenfit Shares Jump 27% After Positive Phase 3 Trial ResultsJune 30, 2023 | msn.comU.S.-listed shares of Genfit soar 24% after positive results from late-stage trial of treatment for rare type of liver diseaseJune 7, 2023 | markets.businessinsider.comGenfit Gears Up For Primary Biliary Cholangitis Trial DataJune 3, 2023 | markets.businessinsider.comGenfit (GNFTF) Receives a Buy from Kepler CapitalApril 21, 2023 | msn.comODDO BHF Maintains Genfit (EPA:GNFT) Buy RecommendationApril 21, 2023 | msn.comSVB SECURITIES Maintains Genfit (EPA:GNFT) Outperform RecommendationJanuary 24, 2023 | benzinga.comGENFIT Announces 2023 Financial CalendarNovember 23, 2022 | seekingalpha.comA Long Wait For Genfit May Be Worth ItSeptember 29, 2022 | nz.finance.yahoo.comGENFIT Announces Signature of the Share Purchase Agreement and the Completion of its Acquisition of VersantisSeptember 19, 2022 | finance.yahoo.comGENFIT to Acquire Clinical-stage Biopharmaceutical Company Versantis, expanding its Portfolio in Liver DiseasesSeptember 14, 2022 | thestreet.comGenfit Tortures Fatty Liver Drug to Extract Positive Results From Failed StudySeptember 13, 2022 | finance.yahoo.comFDA Grants GENFIT’s GNS561 Orphan Drug Designation for the Treatment of CholangiocarcinomaSeptember 12, 2022 | thestreet.comGenfit's French Fans Fume Following Failure of Fatty Liver DrugSeptember 9, 2022 | finance.yahoo.comGenfit S.A. (GNFT)August 20, 2022 | reuters.comGNFT.OQ - Genfit SA (ADR) | Stock Price & Latest News | ReutersAugust 19, 2022 | msn.comAnalyzing Genfit's Short InterestSee More Headlines Receive GNFTF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genfit and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:GNFTF CUSIPN/A CIKN/A Webwww.genfit.com Phone(332) 016-4000FaxN/AEmployees154Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Jean-Francois Mouney (Age 69)Co-Founder & Chairman of the Board Comp: $400.24kMr. M. Pascal Prigent (Age 56)Chief Executive Officer Comp: $606.58kProf. Bart Staels (Age 61)Co-Founder & Chairman of the Scientific Advisory Board Mr. Thomas Baetz (Age 50)Chief Financial Officer Mr. Pascal Caisey (Age 56)Chief Operating Officer Dr. Meriam Kabbaj Ph.D. (Age 50)Chief Technology Officer Dr. Dean W. Hum Ph.D. (Age 62)Chief Scientific Officer Comp: $771.84kMr. Jean-Christophe Marcoux (Age 46)Chief Corporate Affairs Officer, Head of Investor Relations & Head of ESG Mr. Laurent Lannoo (Age 54)Corporate Secretary & Director of Legal Affairs Ms. Stefanie Magner J.D. (Age 43)Chief Compliance Officer & Executive VP of International Legal Affairs More ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors GNFTF Stock Analysis - Frequently Asked Questions How have GNFTF shares performed in 2024? Genfit's stock was trading at $3.45 at the beginning of the year. Since then, GNFTF shares have decreased by 13.6% and is now trading at $2.98. View the best growth stocks for 2024 here. Are investors shorting Genfit? Genfit saw a drop in short interest during the month of February. As of February 15th, there was short interest totaling 42,400 shares, a drop of 69.8% from the January 31st total of 140,300 shares. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio is presently ∞ days. View Genfit's Short Interest. How do I buy shares of Genfit? Shares of GNFTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:GNFTF) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the MarketsOnly a fool would buy Nvidia today… Porter & CompanyBill Gates is all about this tiny $2 stockTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genfit S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.